SEC Tracker
Get the app

Talphera TLPH

Talphera FY 2024: net loss $13.0M

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Talphera reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$13.0MAgainst −$18.4M in FY 202310-K income statement, on EDGAR
  2. Cash and cash equivalents$8.9M+55% from $5.7M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  3. Cash from operations−$12.7MAgainst −$17.5M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Talphera files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biovie BIVI public float $8M, Dec 31, 2025
  2. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
  3. GT Biopharma GTBP public float $9M, Jun 30, 2025
  4. Orgenesis ORGS public float $8M, Jun 30, 2025
  5. TherapeuticsMD TXMD public float $9M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.